TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04279743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 phospholipids
Description: The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening) (4 g/ day of phospholipids), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 Triglycerides
Description: The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele.
Study: NCT04277221

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Dendritic Cell/Tumor Antigen, ADCTA
Description: ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Dendritic Cell/Tumor Antigen, ADCTA
Description: ADCTA is an individualized cell immunotherapy co-culturing autologous dendritic cells derived from peripheral blood mononuclear cells (PBMNCs) with autologous tumor cell as antigen in order to evoke specific immune response.
Study: NCT02772471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HS-1000
Study: NCT04279743

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 Triglycerides
Description: The intervention is a randomized double blind parallel design testing the metabolism of a krill oil omega-3 phospholipid supplement compared to fish oil omega-3 triglycerides in carriers and non-carriers of the ApoE4 allele. Half of the carriers and non-carriers will receive phospholipids and the other half will receive triglycerides. The intervention choice will be randomized and double blind.~Participants will be instructed to take 4 supplements every day (2 in the morning and 2 in the evening), providing 1.8 g/day of omega-3 fatty acids. They will come back fasted to the research center on weeks 0, 1, 2, 3, 4, 8 and 12 of the study for blood draws. The omega-3 fatty acids metabolism will be compared between the carriers and non carriers of the ApoE4 allele.
Study: NCT02877017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family safety reporting intervention
Description: family safety reporting intervention for families and providers
Study: NCT01727934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miravirsen sodium
Description: Subcutaneous injection
Study: NCT01142440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: * Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups
Study: NCT02917343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mirror therapy and repetitive task training
Study: NCT01142440

Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: behavioral intervention
Description: * Dietary instructions~* Oral hygiene instructions: GC plaque indicator kit~* Antibacterial therapy: medident sol. one week a month, for 6 months~* Fluorides: VOCO Profluorid varnish, once every 3 month~* Restoration~* Follow ups
Study: NCT01135472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole Magnesium
Description: NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
Study: NCT01711905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: daily dosage of 20 µg Vitamin D3 for 12 weeks
Study: NCT01001936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606
Study: NCT01075113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT00411957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
Study: NCT02918526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: airway management
Description: airway management with Laryngeal Mask or Oro Tracheal Intubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airway management
Description: airway management with Laryngeal Mask or Oro Tracheal Intubation
Study: NCT01075113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally
Study: NCT00306163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: inhaled Ciclesonide 160 µg, once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone
Description: inhaled Fluticasone 100 µg, twice daily
Study: NCT04078438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neurofeedback augmentation
Description: Neurofeedback training was performed using a Neurocybernetics EEG Biofeedback system (Neurocybernetics Inc., Encino, CA, USA). The neurofeedback protocol was determined by the neurofeedback team, which included 3 psychiatrists, in consideration of the patient's main symptoms.~The neurofeedback augmentation group was asked to participate in 12 weeks of combined therapy of medication and 12-24 sessions of neurofeedback training. Patients in the neurofeedback augmentation group received sensorimotor rhythm (SMR) beta or beta training for 30 minutes, and then alpha/theta (A/T) training for 30 minutes in each session.~To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions. The medication-only (treatment as usual, TAU) group maintained the same medication use as that before the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment as usual
Description: The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: The neurofeedback augmentation group and the medication-only group maintained the same medication use as that before the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: psychotherapy placebo sessions
Description: To reduce the impact of confounding factors, the medication-only (treatment as usual, TAU) group visited at the same schedule as neurofeedback augmentation group and received psychotherapy placebo sessions instead of neurofeedback training sessions. These sessions included psychological assessment and supportive psychotherapy.
Study: NCT00402987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: dose 1 placebo followed 6-12 hours later by dose 2 placebo
Study: NCT00003816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study: NCT04602988

Intervention type: DEVICE
Intervention: EEG
Description: EEG monitoring of brain rhythms
Study: NCT02576002

Intervention type: DRUG
Intervention: Assigned pulmonary hypertension medication
Description: As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
Study: NCT01099605

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placement of a continuous infusion pump
Description: Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion pump of bupivacaine
Description: bupivacaine 0.25% at 4ml/hr for 3 to 4 days
Study: NCT06158373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infant massage practice
Description: infant massage practice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Safe Swaddling
Description: Safe Swaddling

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Control
Study: NCT04015336

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 T-Cell Receptor (TCR)
Description: The dose of E7 T-Cell Receptor (TCR) T cells will be 3 x 10\^10 TCR+ T cells (unless fewer cells are generated) administered once.
Study: NCT04070430

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 weeks of partial weight bearing on crutches
Description: Following surgery, patients will be instructed by their surgeon to use crutches for 2 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 weeks of partial weight bearing on crutches
Description: Following surgery, patients will be instructed by their surgeon to use crutches for 4 weeks, and will follow-up normally, as any patient would. Their crutch use will not impact the quality or style of their postoperative care in any manner. At their 6-week, 6-month, 12-month, and 24 months postoperative visit, the mHHS and NAHS scores will be collected and stored in a secure data system, REDCAPS.
Study: NCT02692170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-001
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVI-HBV-001
Description: Investigational Product

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Hepatitis B vaccine (20 μg)
Description: Investigational Product
Study: NCT01115075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary fat/intake of carbohydrate
Description: Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.
Description: Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
Study: NCT02943018

Intervention type: OTHER
Intervention: anovaginal distance variation
Description: Kappa calculation
Study: NCT05239364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter-based ablation of arrhythmias using radiofrequency.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter ablation
Description: Catheter-based ablation of arrhythmias using radiofrequency.
Study: NCT03649412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Modified Release
Description: GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Modified Release
Description: GSK2982772 MR will be available as MR prototype coated tablet with unit dose strength of 240 mg in Part A. In Part B, GSK2982772 MR prototype coated tablet with unit dose strength of 120 mg (may be changed following interim review of Part B) will be administered by subjects. GSK2982772 MR will be administered orally with 240 milliliter (mL) of water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 Immediate Release
Description: In part A, GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 240 mg (8 tablets of dose strength 30 mg) orally with 240 mL of water
Study: NCT04026685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion
Description: continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine infusion and Ringer-Acetate bolus
Description: continuous phenylephrine infusion started at a rate of 25mcg/min and titrated according to blood pressure plus crystalloid Ringer-Acetate co-loading bolus of 1000 mL
Study: NCT01524913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid
Description: 1 cc hyalgan to be injected into superior joint space

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 1cc celestone (6 mg/cc) will be injected into the joint space

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactated Ringers
Description: 1 cc lactated ringers solution will be injected into the joint space
Study: NCT02416011

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GENERIC
Description: The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eTARGET
Description: The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
Study: NCT01389466

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Step 1
Description: Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
Study: NCT00003816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03195608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lane change assistance system
Description: This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
Study: NCT03399721

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chordate S101
Description: Active treatment: The controller creates air-mediated kinetic oscillations with regulated pressure and frequency during a preset treatment time

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Chordate S101 Placebo
Description: Placebo treatment: Placebo treatment is similar to active treatment, but with no oscillations. It is difficult to discern any difference between active and placebo treatment.
Study: NCT00003816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV
Study: NCT04149626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Sedation using dexmedetomidine (initial bolus dose followed by continuous infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Sedation using midazolam (initial bolus dose followed by continuous infusion)
Study: NCT01389466

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Step 1
Description: Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
Study: NCT00003816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Given twice daily for 3 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Given twice daily for 3 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Given twice daily for 3 days
Study: NCT01677260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg metformin hydrochloride extended release caplet (test drug)
Description: In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 mg metformin hydrochloride prolonged release tablet (reference drug)
Description: In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
Study: NCT04149626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Sedation using remifentanil (initial bolus dose followed by continuous infusion)
Study: NCT05723302

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MIP/MEP
Description: MIP/MEP
Study: NCT03553602

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR Brachytherapy + EBRT + STAD
Description: HDR Brachytherapy implant: 2 fractions of 12 Gy to the prostate/ proximal SV.~EBRT: 50.4 Gy in 28 fractions to the pelvic lymph nodes +/- para-aortic nodes, with SIB up to 70 Gy to the PET- positive lesions.~6 months hormonal therapy(LHRH agonist and anti-androgen\[until end of radiotherapy\])
Study: NCT03561155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot assisted treatment (Amadeo®)
Description: The protocol will consist of exercises as follows:~passive modality , passive/plus modality , assisted therapy and Balloon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: The protocol will consist of exercises as follow:~upper limb mobilization, facilitation of movements and active tasks. The exercises will be focused on improving muscle strength, finger extension and flexion and motor control
Study: NCT04340154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell
Description: CAR-T cells were manufactured from peripheral blood mononuclear cells collected by leukapheresis and frozen for multiple uses. Before each CAR T-cell infusion (day 0), patients received lymphodepleting chemotherapy composing of Fludarabine (30 mg/m2/day) and Cyclophosphamide (250 mg/m2/day) on days -5 to -3. No bridging chemotherapy was given between enrollment and infusion. In sequential CAR-T clinical trials, CAR-T cells will be given twice（anti-CD19 CAR-T first, then anti-CD22 CAR-T). All patients underwent bone marrow (BM) biopsy examination and radiology studies on days 30 and every month to determine the response and remission status. Bone biopsy, MRD status by FCM and RT-PCR (if the patient had fusion gene), and EMDs evaluation by CT/MRI/PET-CT were also conducted before CAR-T cell infusion to determine the disease status.
Study: NCT01652313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: 1 mg/day, tablets for 7 days, orally
Study: NCT01990742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Palliative Care Team (PCTeam)
Description: Palliative care teams will be established and will round with residents in the intervention nursing homes.